1061 related articles for article (PubMed ID: 27752710)
41. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
Bertero E; Prates Roma L; Ameri P; Maack C
Cardiovasc Res; 2018 Jan; 114(1):12-18. PubMed ID: 29016751
[TBL] [Abstract][Full Text] [Related]
42. The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway.
Zhou Y; Wu W
Cell Physiol Biochem; 2017; 41(6):2503-2512. PubMed ID: 28472796
[TBL] [Abstract][Full Text] [Related]
43. Empagliflozin directly improves diastolic function in human heart failure.
Pabel S; Wagner S; Bollenberg H; Bengel P; Kovács Á; Schach C; Tirilomis P; Mustroph J; Renner A; Gummert J; Fischer T; Van Linthout S; Tschöpe C; Streckfuss-Bömeke K; Hasenfuss G; Maier LS; Hamdani N; Sossalla S
Eur J Heart Fail; 2018 Dec; 20(12):1690-1700. PubMed ID: 30328645
[TBL] [Abstract][Full Text] [Related]
44. EMPA-REG OUTCOME: The Nephrologist's Point of View.
Wanner C
Am J Cardiol; 2017 Jul; 120(1S):S59-S67. PubMed ID: 28606346
[TBL] [Abstract][Full Text] [Related]
45. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
Rajasekeran H; Lytvyn Y; Cherney DZ
Kidney Int; 2016 Mar; 89(3):524-6. PubMed ID: 26880444
[TBL] [Abstract][Full Text] [Related]
46. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
Scheen AJ
Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271
[TBL] [Abstract][Full Text] [Related]
47. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
48. Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis.
Chung CC; Lin YK; Chen YC; Kao YH; Yeh YH; Trang NN; Chen YJ
Cardiovasc Diabetol; 2023 Feb; 22(1):27. PubMed ID: 36747205
[TBL] [Abstract][Full Text] [Related]
49. Intracellular levels of Na(+) and TTX-sensitive Na(+) channel current in diabetic rat ventricular cardiomyocytes.
Bilginoglu A; Kandilci HB; Turan B
Cardiovasc Toxicol; 2013 Jun; 13(2):138-47. PubMed ID: 23225150
[TBL] [Abstract][Full Text] [Related]
50. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of Na⁺-H⁺ exchange as a mechanism of rapid cardioprotection by resveratrol.
Thuc LC; Teshima Y; Takahashi N; Nishio S; Fukui A; Kume O; Saito S; Nakagawa M; Saikawa T
Br J Pharmacol; 2012 Jul; 166(6):1745-55. PubMed ID: 22288422
[TBL] [Abstract][Full Text] [Related]
52. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms.
Staels B
Am J Med; 2017 Jun; 130(6S):S30-S39. PubMed ID: 28526184
[TBL] [Abstract][Full Text] [Related]
53. Sgk1-dependent stimulation of cardiac Na+/H+ exchanger Nhe1 by dexamethasone.
Voelkl J; Pasham V; Ahmed MS; Walker B; Szteyn K; Kuhl D; Metzler B; Alesutan I; Lang F
Cell Physiol Biochem; 2013; 32(1):25-38. PubMed ID: 23860121
[TBL] [Abstract][Full Text] [Related]
54. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Filippatos TD; Liontos A; Papakitsou I; Elisaf MS
Postgrad Med; 2019 Mar; 131(2):82-88. PubMed ID: 30757937
[TBL] [Abstract][Full Text] [Related]
55. Chronic inhibition of the Na+/H+ - exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling.
Baartscheer A; Hardziyenka M; Schumacher CA; Belterman CN; van Borren MM; Verkerk AO; Coronel R; Fiolet JW
Br J Pharmacol; 2008 Jul; 154(6):1266-75. PubMed ID: 18493245
[TBL] [Abstract][Full Text] [Related]
56. Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes.
Ng KM; Lau YM; Dhandhania V; Cai ZJ; Lee YK; Lai WH; Tse HF; Siu CW
Sci Rep; 2018 Oct; 8(1):14872. PubMed ID: 30291295
[TBL] [Abstract][Full Text] [Related]
57. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling.
Jhuo SJ; Lin YH; Liu IH; Lin TH; Wu BN; Lee KT; Lai WT
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047815
[TBL] [Abstract][Full Text] [Related]
58. Bradykinin B1 and B2 receptors differentially regulate cardiac Na+-H+ exchanger, Na+-Ca2+ exchanger and Na+-HCO3- symporter.
Sandmann S; Kaschina E; Blume A; Kruse ML; Unger T
Eur J Pharmacol; 2003 Jan; 458(1-2):3-16. PubMed ID: 12498901
[TBL] [Abstract][Full Text] [Related]
59. Sphingosine-1-Phosphate Receptor 1 Regulates Cardiac Function by Modulating Ca2+ Sensitivity and Na+/H+ Exchange and Mediates Protection by Ischemic Preconditioning.
Keul P; van Borren MM; Ghanem A; Müller FU; Baartscheer A; Verkerk AO; Stümpel F; Schulte JS; Hamdani N; Linke WA; van Loenen P; Matus M; Schmitz W; Stypmann J; Tiemann K; Ravesloot JH; Alewijnse AE; Hermann S; Spijkers LJ; Hiller KH; Herr D; Heusch G; Schäfers M; Peters SL; Chun J; Levkau B
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207969
[TBL] [Abstract][Full Text] [Related]
60. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
